title: Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals.
abstract: OBJECTIVE
  To examine the association between nonalcoholic hepatic steatosis (HS) and the activity of the hypothalamo-pituitary-adrenal (HPA) axis, as evaluated by a low-dose dexamethasone suppression test, in obese subjects.
  
  
  METHODS
  In a cross-sectional study, we examined 54 obese, otherwise healthy, individuals with a negligible or zero daily alcohol consumption.
  
  
  METHODS
  HS (by ultrasonography), glucose tolerance status (by oral glucose load), insulin resistance [by homeostasis model assessment (HOMA)] and 1.0 mg postdexamethasone (postdex) suppression cortisol levels were measured.
  
  
  RESULTS
  Subjects with nonalcoholic HS (n = 39) had markedly less suppressed circulating cortisol levels than those without HS (n = 15) (21.9 +/- 2.6 vs. 11.0 +/- 1.4 nmol/l, P < 0.001). In addition, subjects with nonalcoholic HS had significantly higher values of HOMA-insulin resistance score and circulating liver enzymes than their counterparts without HS. Age, body mass index (BMI), waist/hip ratio, plasma glucose concentration (both at fasting and after glucose load), lipids and blood pressure values did not differ significantly between the groups. Females were more represented among those without HS. The marked differences in postdex suppression cortisol levels that were observed between the groups were little affected by adjustment for sex, age, BMI, waist/hip ratio, HOMA-insulin resistance score, plasma lipids and liver enzyme levels. Similarly, in a logistic regression analysis, cortisol levels significantly predicted the presence of nonalcoholic HS (P = 0.032), independently of potential confounders.
  
  
  CONCLUSIONS
  These results suggest that nonalcoholic hepatic steatosis is closely correlated with a subtle, chronic activation of the HPA axis in obese, otherwise healthy, individuals.
authors.affiliation: Division of Endocrinology and Metabolic Diseases, University of Verona, Verona, Italy. giacomo.zoppini@univr.it
authors.forename: Giacomo
authors.initials: G
authors.lastname: Zoppini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Targher
authors.forename: Cristina
authors.initials: C
authors.lastname: Venturi
authors.forename: Cristina
authors.initials: C
authors.lastname: Zamboni
authors.forename: Michele
authors.initials: M
authors.lastname: Muggeo
mesh_terms: D000328:Adult; D003430:Cross-Sectional Studies; D003864:Depression, Chemical; D003907:Dexamethasone; D005234:Fatty Liver / Q000150:complications* / Q000000981:diagnostic imaging / Q000503:physiopathology; D005260:Female; D005938:Glucocorticoids; D005951:Glucose Tolerance Test; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology*; D007333:Insulin Resistance; D008099:Liver / Q000000981:diagnostic imaging; D008297:Male; D009765:Obesity / Q000150:complications* / Q000000981:diagnostic imaging / Q000503:physiopathology; D018709:Statistics, Nonparametric; D014463:Ultrasonography
chemical_list: D005938:Glucocorticoids; D003907:Dexamethasone; D006854:Hydrocortisone